This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Browse

Osteogenic Growth Peptide (OGP)

A 14-aa C-terminal histone H4 fragment circulating naturally in serum; the active short fragment OGP(10-14) (Tyr-Gly-Phe-Gly-Gly) stimulates osteoblast proliferation and bone formation in rodents a…

Aliases (5)
OGP · OGP(10-14) · histone H4 fragment 90-103 · sOGP · synthetic OGP
TYPICAL DOSE
Rodent doses typically 1-50 µg/kg SC or IP, 5×/…
Daily
ROUTE
CYCLE
STORAGE

Overview

What is Osteogenic Growth Peptide (OGP)?

Osteogenic Growth Peptide (OGP) is a 14-amino-acid peptide identical to the C-terminal sequence of histone H4, identified as a regulator of bone formation and hematopoiesis. The active fragment OGP(10-14) retains most biological activity.

Key Benefits

Investigated for bone fracture healing, osteoporosis, and stimulation of bone regeneration. Also reported to enhance hematopoietic stem cell proliferation and improve recovery after marrow injury or chemotherapy.

Mechanism of Action

Binds OGP-binding proteins on osteoblast and stromal cell surfaces, activating Gi/MAPK signaling cascades that drive osteoblast proliferation and differentiation. Also stimulates RANKL-independent bone formation pathways.

Pharmacokinetics

·
PeakHalf-life
Approximate curve — visual aid only, not data-precise PK

Peptide Interactions

In bench/animal studies:
Synergistic

G-CSF (hematopoietic synergy), BMPs (additive osteogenic)

Forum-claimed (low evidence):
Synergistic

BPC-157, TB-500 for "complete recovery stack" — no rigorous data

What to Expect

  • Week 1
    Tolerability and dose-response.
  • Week 2-4
    Early effect window.
  • Week 4-8
    Peak benefit assessment.
  • Week 8+
    Cycle decision point.

Side Effects & Safety

  • Common (>10% users): Unknown — no real safety data
  • Less common: Injection-site reactions
  • Rare-serious (<1% but worth knowing):
    • Theoretical concern: peptide also affects hematopoiesis — could in principle alter blood counts
    • Theoretical concern: any growth factor with mitogenic activity carries hypothetical neoplasia risk if subclinical malignancy present
    • Unknown immunogenicity
  • Specific watch periods: No clinical guidance exists

References

Bab I, et al. (1992) — Histone H4-related osteogenic growth peptide (OGP): a novel circulating stimulator of osteoblastic activity. EMBO J

pubmed.ncbi.nlm.nih.gov · 1992

foundational discovery paper

View Study

Greenberg Z, et al. (1995) — Mitogenic action of osteogenic growth peptide (OGP): role of amino and carboxy-terminal regions and characterization of primary signal transduction pathways. Biochim Biophys Acta

pubmed.ncbi.nlm.nih.gov · 1995

mechanism characterization

View Study

Gabet Y, et al. (2004) — Osteogenic growth peptide modulates fracture callus structural and mechanical properties. Bone

pubmed.ncbi.nlm.nih.gov · 2004

fracture-healing animal model

View Study

Pigossi SC, et al. (2016) — Role of Osteogenic Growth Peptide (OGP) and OGP(10-14) in Bone Regeneration: A Review. Int J Mol Sci

pubmed.ncbi.nlm.nih.gov · 2016

comprehensive review

View Study
Was this helpful?
Your feedback shapes what we research deeper.

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load
Loading…
Continue: Extended research →
Our verdict, decision matrix, deep dives, controversies, sources